Can a transplant drug stop COVID lung damage?
NCT ID NCT04948203
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether the drug sirolimus can prevent lung scarring (fibrosis) in people hospitalized with severe COVID-19 pneumonia. About 60 adults who need extra oxygen will receive sirolimus to see if it reduces the chance of long-term lung damage. The goal is to find a way to protect lungs after a serious COVID-19 infection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sirolimus (also known as rapamycin)
- What this could lead to
- If it works, this could point toward a treatment to prevent permanent lung scarring after severe COVID-19 pneumonia.
- What could go wrong
- This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. Sirolimus can have side effects like increased infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 PNEUMONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Chicago
Chicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Could exercise retrain the heart in long COVID?
- Can AI catch lung scarring that doctors might miss?
- Can brain games and gentle currents lift long COVID brain fog?
- Can a simple inhaled combo keep pneumonia patients off ventilators?
- Can brain training zap long COVID brain fog?